|
Dr. Anders Waas is the Vice President of Business Development at CV Therapeutics. He joined CV Therapeutics in 2004 with over 20 years of experience in the pharmaceutical and medical device industry. From 1992 to 2004 he held a variety of senior development strategic marketing and business development positions at Astra and AstraZeneca. Most recently after the merger of Astra and Zeneca he was Director of Global Licensing in charge of Cardiovascular Global Licensing activities.
Before moving into a dedicated business development role Dr. Waas was the head and Director of Strategic Planning and Business Development for cardiovascular metabolic and gastrointestinal products at Astra responsible for global strategic support-for products such as Losec Nexium Toprol XL Atacand and Exanta-and the overall R&D effort in the cardiovascular metabolic and gastrointestinal areas. Dr. Waas also gained experience in the device industry as a European sales leader and medical advisor at WL Gore & Associates.
Dr. Waas received his DDS from the University of Umea in Sweden. | 